Thermo Fisher Scientific Inc. $TMO Shares Sold by Temasek Holdings Private Ltd

Temasek Holdings Private Ltd decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,143,487 shares of the medical research company’s stock after selling 114,630 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.8% of Temasek Holdings Private Ltd’s investment portfolio, making the stock its 14th largest holding. Temasek Holdings Private Ltd’s holdings in Thermo Fisher Scientific were worth $463,638,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC increased its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $30,000. Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. DiNuzzo Private Wealth Inc. raised its position in Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 61 shares in the last quarter. Finally, HighMark Wealth Management LLC boosted its position in Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after purchasing an additional 45 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. JPMorgan Chase & Co. increased their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. UBS Group increased their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a research report on Thursday, October 23rd. Morgan Stanley increased their target price on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Evercore ISI boosted their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Finally, Citigroup raised their price objective on Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $609.38.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $572.49 on Monday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The company has a market cap of $215.09 billion, a PE ratio of 33.07, a P/E/G ratio of 4.19 and a beta of 0.90. The business has a 50-day simple moving average of $559.70 and a 200-day simple moving average of $486.12.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the previous year, the firm earned $5.28 EPS. The company’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share repurchase plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the transaction, the vice president owned 14,145 shares in the company, valued at approximately $8,085,564.90. This represents a 41.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 17,104 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $65,247,057.48. The trade was a 13.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 149,271 shares of company stock worth $86,507,282 in the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.